史泰瑞斯 STE

Mr. Carestio has served as President and CEO of the Company since July 2021. He served as Senior Vice President and Chief Operating Officer from August 2018 to July 2021. He served as Senior Vice President, Sterilization and Disinfection from February 2018 to August 2018 and as Senior Vice President, STERIS Applied Sterilization Technologies and Life Sciences from August 2015 to February 2018. Mr. Carestio joined STERIS in September 1997.

Karen L. Burton serves as Senior Vice President and Chief Financial Officer. She assumed this role in August 2025. From January 2017 to August 2025, Ms. Burton served as Vice President and Chief Accounting Officer. Previously, Ms. Burton also served as Controller from January 2017 until December 2023. She joined STERIS in September 2004.

Mary Clare Fraser serves as Senior Vice President and Chief Human Resources Officer. She assumed this role in May 2022. She joined STERIS in July 2020 as the Vice President and Chief Human Resources Officer. From February 2003 to July 2020, she held various positions with Parker-Hannifin Corporation, a global motion control technologies company, serving most recently from September 2019 to July 2020, as Vice President Human Resources of its Aerospace Group and from March 2017 to September 2019 as its Corporate Director of Human Resources.

Ms. Feldmann is a retired certified public accountant with 27 years of experience in two large global accounting firms. From 2005 to 2011, Ms. Feldmann served as the Founder and President of Jetty Lane Associates, a consulting firm. From 2003 to 2005, Ms. Feldmann served as the Life Sciences Business Development Officer for the Boston law firm Palmer & Dodge, LLP. From 1994 to 2002, Ms. Feldmann was a partner with KPMG LLP, primarily serving as Partner-in-Charge of its National Medical Technologies Practice. From 1975 to 1994, Ms. Feldmann was employed by Coopers & Lybrand (now PricewaterhouseCoopers LLP), and during that time was named Partner-in-Charge of its Life Sciences practice. Ms. Feldmann served as a director of Hanger, Inc. from 2003 until 2018, as a director of Frequency Therapeutics, Inc. from 2020 until 2023 and as a director of Alexandria Real Estate Equities, Inc. from 2022 until 2025. Ms. Feldmann has served as a director of UFP Technologies, Inc. (NASDAQ: UFPT) since 2017.

Dr. Alegria has served as an Executive Consultant and Advisor with The LaSalle Group, an executive consulting firm, since May 2025. Dr. Alegria has over 25 years of experience in successful advancements of vaccines and therapeutic drugs from R&D through commercialization. Previously, she was the Founder of APIE Therapeutics, a preclinical stage pharmaceutical company, where she served as the Chief Executive Officer from 2020 to 2023 and Chief Innovation Officer from 2023 to 2025. Dr. Alegria founded Catalyst Excel & Advance, an advisory firm providing operational guidance to senior executives working to launch new pharmaceutical and biopharmaceutical companies, which she operated from 2016 to 2020. From 2005 to 2015, Dr. Alegria held positions of increasing responsibility at Biogen, Inc., most recently as Senior Vice President, Global Manufacturing, where she was responsible for the company's successful manufacturing operations in Denmark, Massachusetts and North Carolina. Prior to 2005, Dr. Alegria held positions of increasing responsibilities at Banner Pharmacaps, Inc. and Wyeth (R&D Vaccines). Dr. Alegria served as a director of AVID Bioservices, Inc. from 2021 to 2025. She is currently a member of the Board of Trustees for the Puerto Rico Science, Technology and Research Trust, where she focuses on economic and business development in the life science landscape.

Mr. Martin is the former Senior Vice President & Chief Information Officer of Baxter International, a multinational healthcare company, from January 2011 to October 2020. Mr. Martin has served as a director of Unisys Corporation (NYSE: UIS) since 2017 and Owens Corning (NYSE: OC) since 2021. From January 2021 to October 2022, Mr. Martin served as a member of the board of directors of Ping Identity Holding Corp.

Dr. Shah has served on the faculty of Stanford University since August 2018. From March 2022 to March 2025, Dr. Shah served as the Chief Medical Officer of American Health Associates. Dr. Shah is also co-founder of Qualified Health PBC, which was founded in 2024. Previously, Dr. Shah served from July 2020 through March 2022 as Chief Medical Officer of doc.ai, inc., and its successor, Sharecare Inc., a digital healthcare platform company. Dr. Shah also served as Commissioner of Health of the State of New York from January 2011 to May 2014 and as Senior Vice President and Chief Operating Officer for Clinical Operations for Kaiser Permanente Southern California from May 2014 to October 2017.

Julia K. Madsen serves as Senior Vice President and General Manager, Life Sciences. She assumed this role in July 2020. From August 2015 to July 2020, she served as Vice President and General Manager Life Sciences, Consumables. She joined STERIS in September 1995.

Lindsey M. McGowan serves as Chief Compliance and Quality Officer. She assumed this role in January 2026. From September 2023 to December 2025, she served as Vice President, Quality. From September 2019 to September 2023, she served as Vice President, AST Quality Operations. She joined STERIS in May 2006.

Kenneth E. Kohler serves as Senior Vice President and General Manager, AST. He assumed this role in February 2024. Previously, Mr. Kohler served from November 2015 to February 2024 as Vice President and General Manager of AST Americas. He joined STERIS in May 1988.